/

Empresas

Zy

No verificado

Zymeworks Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasMedicina Salud BienestarVenta al público/Minorista

49 Comunicados de prensa

Ver todos los comunicados de prensa

25/08/2026

Biotecnología

Medicina Salud Bienestar

Anuncios breves

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Fuente

Editor

1.00

0

11/08/2026

Biotecnología

Zymeworks Announces Participation in Upcoming Investor Conferences

Fuente

Editor

1.00

0

29/06/2026

Biotecnología

Zymeworks to Acquire Theravance Biopharma, Inc.

Fuente

Editor

1.00

0

14/06/2026

Biotecnología

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Fuente

Editor

1.00

0

14/05/2026

Biotecnología

Finanzas

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Fuente

Editor

1.00

0

13/05/2026

Biotecnología

Zymeworks Announces Participation in Upcoming Investor Conferences

Fuente

Editor

1.00

0

21/04/2026

Biotecnología

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Fuente

Editor

1.00

0

17/04/2026

Biotecnología

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Fuente

Editor

1.00

0

09/04/2026

Biotecnología

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Fuente

Editor

1.00

0

01/04/2026

Biotecnología

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0